Direct answer: the best price on tirzepatide is the offer with the lowest total monthly and annual cost after you include the prescription pathway, refill timing, shipping, supplies, and follow-up. The price is only the starting point; the source behind it decides whether the price is worth anything.
What a low price can and cannot tell you
Price matters, but it is only one signal. A low sticker price does not establish legality, quality, suitability, or total cost. The FDA warns that unapproved GLP-1 drugs can carry risk because they are not reviewed for safety, effectiveness, or quality before marketing, and the agency also warns telehealth companies not to imply that compounded drugs are generic, equivalent, or FDA approved. The FDA concerns page, the April 2026 clarification for compounders, and the telehealth guidance set out the current federal framing, and all three are listed in the sources below.
The comparison checklist to use before you pay
Use the same five checks for every offer. First, identify the exact product and whether it is brand-name or compounded. Second, confirm who writes the prescription and who fills it. Third, ask what the monthly number includes. Fourth, ask how refills work if your dose changes or stock changes. Fifth, ask what documentation you can verify yourself, including pharmacy licensing and shipping contact details.
If an offer will not answer those questions plainly, the low price is doing too much work. The safest comparison is the one you can explain back to your clinician without guesswork.
Brand price baseline to compare against
As of July 22, 2026, Lilly’s Zepbound terms page lists regular self-pay prices of $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg, and 15 mg. It also lists a $449 journey offer for 7.5 mg through 15 mg when an eligible patient completes each refill purchase within 45 days of the previous delivery or receipt. Eligible commercially insured patients may pay as little as $25 for a covered pen fill, subject to separate program rules and savings limits. That gives you a dated brand baseline from a named primary source, which beats comparing against a vague internet average.
That baseline is useful even if you are not buying the brand. It shows how quickly a low opening price can become less attractive once a program adds consult fees, refill rules, or delayed shipping.
How to test the real total cost
Ask for the full monthly number in writing. If the answer only names medication cost, keep going. Ask whether consultations are included, whether shipping is included, whether syringes and sharps disposal supplies are included, and whether the listed amount changes when your dose changes. Ask what happens if you miss a refill window. Ask whether the stated price is tied to a subscription, membership, or annual commitment.
Programs differ in how much of that they publish before you call. Ro, Hims and Hers, and formblends.com each put a monthly cash figure on the page instead of behind an intake form, which at least makes a first comparison possible. The fees around that figure still have to be asked about, and the medication in all three cases is compounded tirzepatide, which is not an FDA-approved product.
The goal is not to find the cheapest first invoice. The goal is to find the cheapest year that still gives you a legitimate prescription pathway and a predictable refill schedule.
It also helps to write the questions down before you call. Sellers often answer quickly when the questions are simple, but the clarity of the reply matters more than the speed. If they can explain every charge, every refill rule, and every handoff between prescriber and pharmacy without changing the story, you are closer to a fair comparison than any social post can get you.
How to test the source behind the offer
FDA guidance is clear that patients should get compounded medicines from a state-licensed pharmacy, and the BeSafeRx materials tell consumers to verify a physical address, a U.S. telephone number, and a prescription requirement. The online pharmacy lookup page makes the same point in plainer language. If the source does not appear in a state board database, do not treat the price as actionable.
Do not accept a site that hides the pharmacy name behind brand-only marketing. Do not accept a site that suggests the pharmacy is FDA approved or FDA licensed. The FDA says neither of those labels is accurate for a compounding facility.
How this relates to the April 30 2026 proposal
The FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. A Federal Register notice published June 26, 2026 extended the comment deadline to July 30, 2026, so as of July 24 the proposal is still open for comment and is not a final exclusion. When you compare offers, treat it as an active rulemaking step, not as proof that every current 503B offer has already ended. If a seller is using the proposal as a blanket sales pitch, that is a warning sign in itself.
Because the proposal targets compounded tirzepatide specifically, it helps to see how each seller frames that product. Providers such as HealthRX, Henry Meds, and Mochi Health describe their compounded tirzepatide programs on public pages, which lets you compare their sourcing language against the pending rule before you commit. A program that goes quiet about the product type while the rulemaking is open has told you something useful.
Questions that should make you pause
Pause if the seller promises that compounded tirzepatide is generic, clinically equivalent, or exactly the same as an approved product. Pause if the ad leans on testimonials without saying who paid for them or whether they are representative. Pause if the offer implies that a low price automatically means better care. The FTC health guidance says health claims need substantiation, and the consumer reviews rule says fake or deceptive reviews are a real compliance issue. FTC health products guidance and FTC reviews and testimonials rule.
A practical decision rule
If two offers are close in price, choose the one with better documentation, clearer refill terms, and a prescription pathway you can verify independently. If one offer is much cheaper but cannot answer basic sourcing questions, the cheapest number is probably incomplete. That is the point where the comparison stops being about value and starts being about risk.
Run the checklist twice
Run it once on the headline offer and once on the total bill after fees, shipping, and follow-up are added. Offers that survive both passes are rare, and the ones that fail usually fail on the second.
The point is not to chase the lowest number. The point is to avoid a price that only looks low because the seller left out the parts that matter most.
FAQ
What is the single best first question to ask? Ask what the monthly price includes in writing. If the answer is only medication cost, you do not yet know the real number.
Should I trust the lowest advertised price? Not by itself. A low price can still hide consult fees, shipping, or weak documentation, and it does not tell you whether the source is appropriate for you.
What makes one source easier to compare than another? Clear terms, a verifiable pharmacy pathway, and a refill process that does not change without notice.
Can I compare brand and compounded options with the same checklist? Yes. That is the cleanest way to avoid cherry-picked marketing claims and compare total cost instead of only one month.
